Latest news with #DavidGate
Business Wire
2 days ago
- Health
- Business Wire
Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration leverages Tempus' AI-powered data analytics platform, Lens, to analyze and restructure the Center's repository of genomic data. Together, the Center and Tempus teams will work to uncover genomic patterns that have the potential to advance the understanding of Alzheimer's disease, investigate the gene and cell types affected, enable the development of new therapeutics, and accelerate the creation of novel clinical applications. By harnessing Lens' advanced AI capabilities, the collaboration aims to generate actionable insights that drive the discovery of targeted therapies and significantly improve patient outcomes. 'We are excited to collaborate with the Abrams Research Center on Neurogenomics to confront one of the most complex and pressing medical challenges of our time,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'By integrating our AI platform with the Center's pioneering work in neurogenomics, we are opening new avenues for discovery. Together, we strive to advance research for Alzheimer's and bring hope and tangible impact to patients and families affected by this devastating disease.' 'This collaboration with Tempus represents an important step forward in our mission to harness cutting-edge technologies to transform Alzheimer's research,' said David Gate, PhD, assistant professor in Ken and Ruth Davee Department of Neurology at Feinberg and head of The Abrams Research Center on Neurogenomics. 'We share a commitment to deepen our understanding of the genomic underpinnings of Alzheimer's disease and accelerate the development of more targeted, effective interventions.' About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding the expected outcomes and benefits of the collaboration with the Abrams Research Center on Neurogenomics to advance research for Alzheimer's disease are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Yahoo
12-03-2025
- Health
- Yahoo
Brain's immune system could treat Alzheimer's: Study
(NewsNation) — New research suggests enhancing the brain's own immune cells could help clear plaques associated with Alzheimer's disease. Research indicates amyloid beta plaques, sticky clumps of protein that accumulate in the brain, contribute to Alzheimer's disease. The main theory on Alzheimer's development is the amyloid cascade hypothesis, which suggests that the accumulation of amyloid beta plaques triggers a series of events, including the accumulation of tau proteins, which result in the symptoms of the disease. California dad sees ambulance bill more than double with insurance If the plaques could be cleared before tau proteins begin to accumulate, it could prevent cognitive decline. The new findings, published in Nature Medicine, could help shift the future of treatment, leading to efforts to harness the brain's natural defenses against the disease. Treatment for Alzheimer's remains limited. An earlier attempt at an Alzheimer's vaccine failed after the immune response caused dangerous brain swelling. There are FDA-approved antibody treatments, but they remain controversial, offering modest results while coming with potential side effects and high costs. There are drugs that stimulate the immune system to remove amyloid beta plaques, said author David Gate, but he believes the data they gathered could make the drugs more effective. Texas measles outbreak hits 223 cases, 29 hospitalized Scientists compared brain tissue from deceased people with Alzheimer's who received amyloid-beta immunization and those who did not. They found that not only did immune cells called microglia clear plaques, but they also helped restore the brain to a healthier level. However, researchers also found that some microglia were more effective in plaques than others and that the region of the brain treated and the type of immunization played a role in how they worked. Scientists currently have no way to target specific immune cells that are associated with plaque clearing, but scientists say methods of targeting cells in the brain are improving. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
